This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis for the CHMP recommendations, read the scientific discussion (also part of the EPAR).
Therapeutic Indication
### Therapeutic indication Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
Therapeutic Area (MeSH)
N/AATC Code
N06DA03
ATC Item
rivastigmine
Pharmacotherapeutic Group
Psychoanaleptics
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| rivastigmine | N/A | 利斯的明 |
EMA Name
Rivastigmine Sandoz
Medicine Name
Rivastigmine Sandoz
Aliases
N/ANo risk management plan link.
